CHF and arrhythmias:
Indications for: JARDIANCE
To reduce the risk of cardiovascular death plus hospitalization for heart failure (HF) in adults with HF and reduced ejection fraction.
Adult Dosage:
Take in the AM. 10mg once daily. HF with reduced ejection fraction (with eGFR <20mL/min/1.73m2): insufficient data for dosing.
Children Dosage:
<18yrs: not established.
JARDIANCE Contraindications:
Patients on dialysis.
JARDIANCE Warnings/Precautions:
Correct volume depletion before initiating. Increased risk for volume depletion or hypotension in those with renal impairment (eGFR <60mL/min/1.73m2), elderly, or on loop diuretics. Assess volume status and renal function prior to initiation; monitor during therapy. Assess for ketoacidosis in presence of signs/symptoms of metabolic acidosis, regardless of blood glucose levels; discontinue if suspected, evaluate and treat; consider risk factors before initiation (eg, pancreatic insulin deficiency, caloric restriction, alcohol abuse). Consider temporarily discontinuing prior to scheduled surgery (for ≥3 days) or other clinical situations (eg, prolonged fasting due to illness or post-surgery). Necrotizing fasciitis of the perineum (Fournier's gangrene); discontinue and treat immediately if suspected; use alternative antidiabetic. Increased risk of genital mycotic infections or UTIs; monitor and treat appropriately. Discontinue if hypersensitivity reaction occurs; treat promptly and monitor until resolve. Elderly. Pregnancy (during 2nd & 3rd trimesters), nursing mothers: not recommended.
JARDIANCE Classification:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor.
JARDIANCE Interactions:
Greater potential for volume depletion with concomitant diuretics. Consider a lower dose of concomitant insulin or insulin secretagogue (eg, sulfonylurea) to reduce risk of hypoglycemia. May result in false (+) urine glucose tests or unreliable measurements of 1,5-AG assay; use alternative methods to monitor glycemic control.
Adverse Reactions:
UTIs, female genital mycotic infections, increased urination; hypotension, ketoacidosis, renal impairment, urosepsis, pyelonephritis, angioedema; rare: Fournier's gangrene.
Generic Drug Availability:
NO
How Supplied:
Tabs—30, 90
Pricing for JARDIANCE
Diabetes:
Indications for: JARDIANCE
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). To reduce the risk of cardiovascular (CV) death in adults with T2DM and established CV disease.
Limitations of Use:
Not recommended in those with type 1 diabetes; may increase risk of diabetic ketoacidosis. Not recommended in adults with T2DM with an eGFR <30mL/min/1.73m2.
Adult Dosage:
Take in the AM. Initially 10mg once daily; may increase to 25mg, if tolerated. T2DM and established CV disease (with eGFR <30mL/min/1.73m2): insufficient data for dosing.
Children Dosage:
<18yrs: not established.
JARDIANCE Contraindications:
Patients on dialysis.
JARDIANCE Warnings/Precautions:
Correct volume depletion before initiating. Increased risk for volume depletion or hypotension in those with renal impairment (eGFR <60mL/min/1.73m2), elderly, or on loop diuretics. Assess volume status and renal function prior to initiation; monitor during therapy. Assess for ketoacidosis in presence of signs/symptoms of metabolic acidosis, regardless of blood glucose levels; discontinue if suspected, evaluate and treat; consider risk factors before initiation (eg, pancreatic insulin deficiency, caloric restriction, alcohol abuse). Consider temporarily discontinuing prior to scheduled surgery (for ≥3 days) or other clinical situations (eg, prolonged fasting due to illness or post-surgery). Necrotizing fasciitis of the perineum (Fournier's gangrene); discontinue and treat immediately if suspected; use alternative antidiabetic. Increased risk of genital mycotic infections or UTIs; monitor and treat appropriately. Discontinue if hypersensitivity reaction occurs; treat promptly and monitor until resolve. Elderly. Pregnancy (during 2nd & 3rd trimesters), nursing mothers: not recommended.
JARDIANCE Classification:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor.
JARDIANCE Interactions:
Greater potential for volume depletion with concomitant diuretics. Consider a lower dose of concomitant insulin or insulin secretagogue (eg, sulfonylurea) to reduce risk of hypoglycemia. May result in false (+) urine glucose tests or unreliable measurements of 1,5-AG assay; use alternative methods to monitor glycemic control.
Adverse Reactions:
UTIs, female genital mycotic infections, increased urination; hypotension, ketoacidosis, renal impairment, urosepsis, pyelonephritis, angioedema; rare: Fournier's gangrene.
Generic Drug Availability:
NO
How Supplied:
Tabs—30, 90
